Cited by 361Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index, and 2 are not checked yet.

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Open access

Gold, Michael, Alderton, Claire, Zvartau-Hind, Marina, Egginton, Sally, Saunders, Ann M., Irizarry, Michael, Craft, Suzanne, Landreth, Gary, Linnamägi, Ülla, Sawchak, Sharon·2010·Dementia and Geriatric Cognitive Disorders

DOI 10.1159/000318845PMC PMC3214882

Open this paper in CoChat — free account

Abstract

Background/Aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-Ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR. Methods: This double-blind, randomized, placebo-controlled study enrolled 693 subjects. Within 2 APOE allelic strata (Ε4-positive, Ε4-negative), subjects were randomized (2:2:2:1) to once-daily placebo, 2 mg RSG XR, 8 mg RSG XR or 10 mg donepezil (control). Coprimary endpoints were change from baseline to week 24 in the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) score, and week 24 Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+). Results: At week 24, no significant differences from placebo in change from baseline in coprimary endpoints were detected with either the RSG XR dose in APOE-Ε4-negative subjects or overall. For donepezil, no significant treatment difference was detected in ADAS-Cog; however, a significant difference was detected (p = 0.009) on the CIBIC+. Peripheral edema was the most common adverse event for 8 mg RSG XR (15%) and placebo (5%), and nasopharyngitis for 2 mg RSG XR (7%). Conclusion: No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-Ε4-negative or other analysis populations. The safety and tolerability of RSG XR was consistent with its known pharmacology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1159/000318845

Cites

56 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Alzheimer’s disease
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Development of a Functional Measure for Persons With Alzheimer’s Disease: The Disability Assessment for Dementia
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 918
Untitled work
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870

Flagged first, then by citations

Show all 56 references

Sorted by citations

Items 101–200 of 361

Disease-modifying drugs in Alzheimer's disease
Scarpini, E. A., Galimberti, D., & Ghezzi, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41431 · Cited by 74
The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis
Cheng, H., Shang, Y., Jiang, L., Shi, T., & Wang, L. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1015722 · Cited by 74
Therapeutic potential of nuclear receptor agonists in Alzheimer's disease
Moutinho, M., & Landreth, G. E. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075556 · Cited by 76
Self-citation
Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer’s Disease
Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V. D., & Amin, R. (2018) · PPAR Research · doi:10.1155/2018/2010675 · Cited by 77
Treatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation
Aaseth, J., Alexander, J., Bjørklund, G., Hestad, K. A., Dušek, P., Roos, P. M., & Alehagen, U. (2016) · BioMetals · doi:10.1007/s10534-016-9959-8 · Cited by 75
Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes
Lourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 74
Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Insulin: An Emerging Treatment for Alzheimer’s Disease Dementia?
Morris, J. K., & Burns, J. M. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0297-0 · Cited by 72
Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047739 · Cited by 71
Role of PPAR γ in the Differentiation and Function of Neurons
Quintanilla, R. A., Utreras, E., & Cabezas-Opazo, F. (2014) · PPAR Research · doi:10.1155/2014/768594 · Cited by 71
Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
Michailidis, M., Tata, D. Α., Μoraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P. K., & Papaliagkas, V. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094641 · Cited by 71
Alzheimer’s Disease: A Clinical Practice-Oriented Review
Alves, L., Correia, A. S., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 74
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis
d’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation
Willems, S., Zaienne, D., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00186 · Cited by 66
Retracted: Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice
Wang, P., Su, C., Li, R., Wang, H., Ren, Y., Sun, H., Yang, J., Sun, J., Shi, J., Tian, J., et al. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23322 · Cited by 65
Retracted
The importance of BDNF and RAGE in diabetes-induced dementia
Kim, O. Y., & Song, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105083 · Cited by 65
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020542 · Cited by 80
Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease
Chang, K. L., Pee, H. N., Yang, S., & Ho, P. C. (2015) · Scientific Reports · doi:10.1038/srep09000 · Cited by 65
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 71
Self-citation
Towards PET imaging of the dynamic phenotypes of microglia
Beaino, W., Janssen, B., Vugts, D. J., de Vries, H. E., & Windhorst, A. D. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13649 · Cited by 63
New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer’s disease
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes
Palleria, C., Leporini, C., Maida, F., Succurro, E., Sarro, G. D., Arturi, F., & Russo, E. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.07.002 · Cited by 61
Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Sastre, M., Richardson, J. C., Gentleman, S., & Brooks, D. J. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256062 · Cited by 59
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.010 · Cited by 58
Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review
Valenti, R., Pantoni, L., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0160-z · Cited by 57
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 65
Connecting the Dots Between Hypercholesterolemia and Alzheimer’s Disease: A Potential Mechanism Based on 27-Hydroxycholesterol
Wu, M., Zhai, Y., Liang, X., Chen, W., Lin, R., Ma, L., Huang, Y., Zhao, D., Liang, Y., Zhao, W., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.842814 · Cited by 59
Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease
de la Monte, S. M. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e482 · Cited by 57
Antidiabetic Drugs in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review
Muñoz-Jiménez, M., Zaarkti, A., García-Arnés, J. A., & García‐Casares, N. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000510677 · Cited by 55
An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer’s Disease
Chamberlain, S. D., Gabriel, H., Strittmatter, W. J., & Didsbury, J. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190864 · Cited by 55
Cross-Sectional Association between Polyfluoroalkyl Chemicals and Cognitive Limitation in the National Health and Nutrition Examination Survey
Power, M. C., Webster, T. F., Baccarelli, A., & Weisskopf, M. G. (2012) · Neuroepidemiology · doi:10.1159/000342310 · Cited by 55
Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation
Moutinho, M., Codocedo, J. F., Puntambekar, S. S., & Landreth, G. E. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021807 · Cited by 57
Self-citation
Targeting Insulin Resistance to Treat Cognitive Dysfunction
Tyagi, A., & Pugazhenthi, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02283-3 · Cited by 59
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate
Pizcueta, P. M., Vergara, C., Emanuele, M., Vilalta, A., Rodríguez‐Pascau, L., & Martinell, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043201 · Cited by 55
Peroxisome Proliferator-Activated Receptor-Gamma Agonists for Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
Liu, J., Wang, L., & Jia, J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0228-7 · Cited by 53
Brain clearance of protein aggregates: a close-up on astrocytes
Giusti, V., Kaur, G., Giusto, E., & Civiero, L. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00703-1 · Cited by 54
Impaired Insulin Signaling and Mechanisms of Memory Loss
Bloemer, J., Bhattacharya, S., Amin, R., & Suppiramaniam, V. D. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00013-2 · Cited by 52
Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND
Seaquist, E. R., Miller, M. E., Fonseca, V. A., Ismail‐Beigi, F., Launer, L. J., Punthakee, Z., & Sood, A. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.03.005 · Cited by 51
Rosiglitazone activation of PPARγ-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta–induced mitochondrial dysfunction and oxidative stress
Chiang, M., Nicol, C. J. B., Cheng, Y., Lin, K., Yen, C., & Lin, C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.132 · Cited by 52
Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review
Dailah, H. G. (2022) · Molecules · doi:10.3390/molecules27217207 · Cited by 51
Towards universal therapeutics for memory disorders
Sun, M., Nelson, T. J., & Alkon, D. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.004 · Cited by 51
A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
ESTERLINE, R. L., Oscarsson, J., & Burns, J. M. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 51
Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Zolochevska, O., & Taglialatela, G. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160518142110 · Cited by 49
Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Sureda, F. X., Junyent, F., Verdaguer, E., Auladell, C., Pelegrí, C., Vilaplana, J., Folch, J., Canudas, A. M., Zárate, C. B., Pallàs, M., et al. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049732 · Cited by 49
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease
Suzanne, M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/482 · Cited by 50
Molecular and biochemical trajectories from diabetes to Alzheimer’s disease: A critical appraisal
Sandhir, R., & Gupta, S. N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1223 · Cited by 49
Type 2 Diabetes Mellitus Drugs for Alzheimer’s Disease: Current Evidence and Therapeutic Opportunities
Meng, L., Li, X., Shen, L., & Ji, H. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.002 · Cited by 49
Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
Cummings, J. L., Ortiz, A. A., Castellino, J., & Kinney, J. W. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15619 · Cited by 54
Type 2 Diabetes and Cognitive Compromise
Kravitz, E., Schmeidler, J., & Beeri, M. S. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.009 · Cited by 49
Psychiatric Disorders Presenting in the Elderly With Type 2 Diabetes Mellitus
Alagiakrishnan, K., & Sclater, A. L. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31823038db · Cited by 51
Status and future directions of clinical trials in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 49
The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment
Moon, J. H., Kim, H. J., Yang, A. H., Kim, H. M., Lee, B., Kang, E. S., Lee, H. C., & Soo, B. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001611 · Cited by 47
Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies
Slater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 47
A meta‐analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil
Pisani, S., Mueller, C., Huntley, J. D., Aarsland, D., & Kempton, M. J. (2021) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5581 · Cited by 53
Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α
Sáez-Orellana, F., Octave, J., & Pierrot, N. (2020) · Cells · doi:10.3390/cells9051215 · Cited by 47
Effects of Pioglitazone or Exercise in Older Adults with Mild Cognitive Impairment and Insulin Resistance: A Pilot Study
Hildreth, K. L., Pelt, R. E. V., Moreau, K. L., Grigsby, J., Hoth, K. F., Pelak, V. S., Anderson, C. A., Parnes, B. L., Kittelson, J. M., Wolfe, P., et al. (2015) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000371509 · Cited by 46
Sulfur-containing therapeutics in the treatment of Alzheimer’s disease
Zhu, H., Dronamraju, V., Xie, W., & More, S. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02687-1 · Cited by 46
Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimerʼs Disease Relieve Caregiver Burden?
Levy, K. S., Lanctôt, K. L., Farber, S. B., Li, A., & Herrmann, N. (2012) · Drugs & Aging · doi:10.2165/11599140-000000000-00000 · Cited by 43
The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia
Sečník, J., Xu, H., Schwertner, E., Hammar, N., Alvarsson, M., Winblad, B. G., Eriksdotter, M., Ptacek, S. G., & Religa, D. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00934-0 · Cited by 44
Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease
Marek, G. J., Katz, D. A., Meier, A., Greco, N., Zhang, W., Liu, W., & Lenz, R. A. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.010 · Cited by 42
Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes
Ascher‐Svanum, H., Chen, Y.-F., Hake, A. M., Kahle‐Wrobleski, K., Schuster, D., Kendall, D. M., & Heine, R. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.01.002 · Cited by 43
Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development
Singh, D. D., Shati, A. A., Alfaifi, M. Y., Elbehairi, S. E. I., Han, I., Choi, E. H., & Yadav, D. K. (2022) · Cells · doi:10.3390/cells11233767 · Cited by 42
Considering a new paradigm for Alzheimer's disease research
Langley, G. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.013 · Cited by 42
Psychometric evaluation of ADAS-Cog and NTB for measuring drug response
Karin, A. A., Hannesdóttir, K., Jaeger, J., Annas, P., Segerdahl, M., Karlsson, P., Sjögren, N., von Rosen, T., & Miller, F. (2013) · Acta Neurologica Scandinavica · doi:10.1111/ane.12153 · Cited by 41
Mitochondrial Dysfunction in Alzheimer’s Disease and Progress in Mitochondria-Targeted Therapeutics
Flannery, P. J., & Trushina, E. V. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00179-0 · Cited by 41
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
Katsenos, A. P., Davri, A. S., Simos, Y. V., Nikas, I. P., Bekiari, C., Paschou, S. Α., Peschos, D., Konitsiotis, S., Vezyraki, P., & Tsamis, K. I. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2022122 · Cited by 41
Potentials of peroxisome proliferator-activated receptor (PPAR) α, β/δ, and γ: An in-depth and comprehensive review of their molecular mechanisms, cellular Signalling, immune responses and therapeutic implications in multiple diseases
Singh, A., & Chaudhary, R. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114616 · Cited by 42
Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease
Kennedy, R., Cutter, G., & Schneider, L. S. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.03.003 · Cited by 42
Effects of curcumin on synapses in APPswe/PS1dE9 mice
He, Y., Wang, P., Wei, P., Feng, H., Ren, Y., Yang, J.-D., Rao, Y., Shi, J., & Tian, J. (2016) · International Journal of Immunopathology and Pharmacology · doi:10.1177/0394632016638099 · Cited by 38
What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials
Bullain, S., & Doody, R. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 40
Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Bazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190301111120 · Cited by 39
Cyanidin 3- O -β-glucopyranoside activates peroxisome proliferator-activated receptor-γ and alleviates cognitive impairment in the APP swe /PS1 ΔE9 mouse model
Song, N., Zhang, L., Chen, W., Zhu, H., Deng, W., Han, Y., Guo, J., & Qin, C. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.016 · Cited by 36
A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases
Klegeris, A., Madeira, J., & Schindler, S. M. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.153686 · Cited by 36
Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses
Xu, S., Guan, Q., Wang, C., Wei, X., Chen, X., Zheng, B., An, P., Zhang, J., Chang, L. Y., Zhou, W., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.06.010 · Cited by 36
Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology
Malek‐Ahmadi, M. H., Chen, K., Perez, S. E., He, A., & Mufson, E. J. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0401-z · Cited by 38
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
Rosiglitazone Prevents Amyloid-β Oligomer-Induced Impairment of Synapse Formation and Plasticity via Increasing Dendrite and Spine Mitochondrial Number
Xu, S., Guilan, L., Bao, X., Wu, J., Li, S., Zheng, B., Anwyl, R., & Wang, Q. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130680 · Cited by 35
Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer’s disease
Sodhi, R. K., Singh, N., & Jaggi, A. S. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0654-6 · Cited by 36
New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
Wilkins, H., & Morris, J. K. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 34
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Improving Alzheimer's disease phase II clinical trials
Greenberg, B., Carrillo, M. C., Ryan, J. M., Gold, M., Gallagher, K., Grundman, M., Berman, R., Ashwood, T., & Siemers, E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.02.002 · Cited by 34
Self-citation
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis
Veroniki, A. A., Ashoor, H. M., Rios, P. D. L., Seitidis, G., Stewart, L. A., Clarke, M. J., Smith, C. T., Mavridis, D., Hemmelgarn, B. R., Holroyd-Leduc, J. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-053012 · Cited by 33
Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials
Mantik, K. E. K., Kim, S., Gu, B., Moon, S., Kwak, H., Park, D., & Kang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411450 · Cited by 36
Alzheimer’s Disease (AD) Therapeutics—2: Beyond Amyloid—Re-Defining AD and Its Causality to Discover Effective Therapeutics
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Association Between Type 2 Diabetes Mellitus and Alzheimer's Disease: Common Molecular Mechanism and Therapeutic Targets
Chauhan, A., Dubey, S., & Jain, S. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4111 · Cited by 35
Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats
Sain, H. M., Sharma, B., Jaggi, A. S., & Singh, N. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.002 · Cited by 32
New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer’s Disease
Zhong, K. L., Chen, F., Hong, H., Ke, X., Lv, Y., Tang, S. S., & Zhu, Y. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0227-1 · Cited by 33
MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease
Pohland, M., Pellowska, M., Asseburg, H., Hagl, S., Reutzel, M., Joppe, A., Berressem, D., Eckert, S. H., Wurglics, M., Schubert‐Zsilavecz, M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0342-6 · Cited by 33
Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions
Lee, J. H., Jahrling, J. B., Denner, L. A., & Dineley, K. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179923 · Cited by 36
Alzheimer’s Disease: Future Treatments
Morley, J. E. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.10.008 · Cited by 31
Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents
Shakour, N., Sahebkar, A., Karimi, G., Paseban, M., Tasbandi, A., Mosaffa, F., Tayarani‐Najaran, Z., Ghodsi, R., & Hadizadeh, F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105162 · Cited by 30
A metabolic perspective of late onset Alzheimer’s disease
Ettcheto, M., Cano, A. C., Busquets, O., Manzine, P. R., Sánchez‐López, E., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., García, M. L., Olloquequi, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104255 · Cited by 31
Antidiabetic therapies and Alzheimer disease.
Bendlin, B. B. (2019) · PubMed Central · Cited by 30
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum
Bieger, A., Rocha, A., Bellaver, B., Machado, L. S., Ros, L. U. D., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S. G., et al. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.54 · Cited by 29
Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer’s Disease: Potential and Challenges
Jain, S., Singh, R., Paliwal, S., & Sharma, S. K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230511122435 · Cited by 35
The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease
Yu, H.-J., & Koh, S. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.18 · Cited by 30

Authors: Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S.
Affiliations: GlaxoSmithKline (United Kingdom) (GB)
Duke University (US)
University of Washington (US)
Case Comprehensive Cancer Center (US)
University of Tartu (EE)
ORCID: Alderton, Claire
Saunders, Ann M.
Irizarry, Michael
Craft, Suzanne
Landreth, Gary
Venue: Dementia and Geriatric Cognitive Disorders
Publisher: S. Karger AG
Published: 2010
Volume: 30
Issue: 2
Pages: 131-146
ISSN: 1420-8008 (ISSN-L)
1421-9824
DOI: 10.1159/000318845
PMC: PMC3214882
OpenAlex: W1978999542
Cited by: 361
References: 56
Citations by year: 2026: 12 · 2025: 17 · 2024: 20 · 2023: 21 · 2022: 23 · 2021: 25 · 2020: 26 · 2019: 22 · 2018: 22 · 2017: 19 · 2016: 22 · 2015: 24 · 2014: 24 · 2013: 25 · 2012: 31
FWCI: 18.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Dementia and Geriatric Cognitive Disorders (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
National Institute on Aging (R01AG030482)
National Institute of Neurological Disorders and Stroke
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, peroxisome proliferator-activated receptor gamma agonists, APOE ε4 genotype, donepezil, cognitive function, global function, peripheral edema, drug safety and tolerability, ADAS-Cog
MeSH terms: Rosiglitazone, Donepezil, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Cholinesterase Inhibitors, Edema, Female, Genotype, Humans, Hypoglycemic Agents, Indans, Intelligence Tests, Interview, Psychological, Male, Middle Aged, Nasopharyngitis, Piperidines, Treatment Outcome, Thiazolidinediones, PPAR gamma, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks